Basic Information
| Clone | Dupilumab Biosimilar |
|---|
| Molecular Weight | 150 kDa |
|---|
| Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
|---|
| Sterility | 0.2 μm filtration |
|---|
| Aggregation | <5% Determined by SECP |
|---|
| Purity | >95% Determined by SDS-PAGE |
|---|
Product Information
| Production | Purified from cell culture supernatant in an animal-free facility |
|---|
| Purification | Protein A or G purification |
|---|
| Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
|---|
Target Background
What is dupilumab biosimilar research grade? Dupilumab is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis. Dupilumab binds to the alpha subunit of the interleukin-4 receptor (IL-4Ra), making it a receptor antagonist. Through blockade of IL-4Ra, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathways. Dupilumab biosimilar uses the same protein sequences as the therapeutic antibody dupilumab.
Immunogen Information
| Isotype | Human IgG1 kappa |
|---|
| Immunogen | Human IL4R alpha |
|---|
| RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
|---|
| Recommended Dilution Buffer | 1×PBS pH 7.0 |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
i_FC_01.jpg?t=1711071489)
U1_FC_01.jpg?t=1714293774)
